| What is RSS feed? | About Us |
 |
 Search Score: 4/10
Source: news.google.com --- 36 days ago
Enews 2.0 Pfizer Osteoporosis Drug Benefits Outweigh Risks, FDA Panel Says Wall Street Journal - 2 hours ago By JARED A. FAVOLE ROCKVILLE, Md. -- A Panel of medical experts on Monday said the benefits of Pfizer Inc.'s proposed osteoporosis drug, Fablyn, outweigh the risks. UPDATE 1-US FDA Panel backs Pfizer osteoporosis drug Reuters FDA Panel: Pfizer Osteoporosis Drug's Benefits Outweigh Risks CNNMoney.com Bloomberg - Wall Street Journal Blogs - Forbes all 36 news articles ... Source: news.google.com --- 37 days ago
ABC News Pfizer to Pitch Treatment For Osteoporosis to FDA Panel Wall Street Journal - 1 hour ago By JARED A. FAVOLE and SHIRLEY S. WANG Pfizer Inc. is due to appear Monday before outside medical experts and Food and Drug Administration officials to make a case for allowing its Fablyn osteoporosis drug on the market. FDA to List Drugs Being Investigated Washington Post FDA lists 20 drugs for their potential risks Food Consumer U.S. News & World Report - WebMD - Los Angeles Times - ABC News all 563 news articles ... Source: blogs.wsj.com --- 36 days ago
An FDA advisory committee said the benefits of the osteoporosis drug outweigh the risks. But some Panel members suggested the drug be restricted to women at high risk of bone trouble. ... Source: www.jsonline.com --- 3 days ago
A retired medical supply manufacturer who considers bisphenol A to be perfectly safe gave $5 million to the research center of Martin Philbert, chairman of the Food and Drug Association Panel about to make a pivotal ruling on the chemicals s... ... Source: blogs.jsonline.com --- 19 hours ago
Our Sunday story is prompting the Food and Drug Administration to look into whether Martin Philbert' should have disclosed a $5 million his center got from an outspoken anti-regulation activist. The big question is, did that money influence Philbert's role as chairman of a Panel studying the safety of bisphenol A? You can read all about it in our paper on Wednesday. Meanwhile, here are the letters the FDA got today demanding the probe. ... Source: www.medicalnewstoday.com --- 35 days ago
A Panel that advises the US Food and Drug Administration (FDA) on new drug approvals said the benefits of Pfizer's bone drug Fablyn for treating postmenopausal women with osteoporosis outweighed the risks but that use should be restricted to patients at high risk of fracture or who have tried other treatments without success. ... Source: www.medicalnewstoday.com --- 27 days ago
As the US Food and Drug Administration (FDA) awaits final recommendations from an expert Panel, the agency is tentatively defending its current position that products made with BPA (bisphenol A) are safe, while also giving tips to consumers on how to reduce their exposure to the chemical which can be found in trace amounts in over 90 per cent of people in the US. The current view from the FDA is that the levels are too low to cause harm, even in babies and children. ... Source: www.healthcentral.com --- 36 days ago
Members of a U.S. advisory Panel said on Monday they could not determine if a proposed Pfizer Inc drug for osteoporosis increased the chances of dying. ... Source: www.healthcentral.com --- 33 days ago
In studies, Fablyn was shown to be effective at treating osteoporosis in postmenopausal women at high risk of bone fracture, but it has also been linked to an increased risk of blood clots and gynecological problems. ... Source: www.xconomy.com --- 19 hours ago
Targanta Therapeutics is getting ready for a day next month that will go a long way toward determining whether it can sell its first marketed product. The Cambridge, MA-based biotech company, said it has been asked to appear before an FDA advisory committee on Nov. 19 to make its case for why regulators should approve [...] ... Source: www.pharmalot.com --- 36 days ago
Despite a plethoria of safety issues raised by FDA reviewers in their briefing document, an agency advisory committee decided that the benefits of Pfizer’s Fablyn outweighs the risks for women past menopause. The Panel voted 9-3 with one abstention in favor of Fablyn, which Pfizer developed with Ligand Pharmaceuticals, Reuters writes. Members felt Fablyn would be [...] ... Source: www.healthnews.com --- 34 days ago
Fablyn, an experimental drug manufactured by Pfizer Inc. for treatment of osteoporosis, has been determined by the FDA to have health benefits that outweigh its risks. The FDA Panel met in Rockville, Maryland and voted 9-3 to recommend the drug for postmenopausal women with osteoporosis. read more ... Source: www.fwicki.com --- 35 days ago
ROCKVILLE, Maryland (Reuters) - Members of a U.S. advisory Panel said on Monday they could not determine if a proposed Pfizer Inc drug for osteoporosis increased the chances of dying. Seven members of the Food and Drug Administration committee said ... ... Source: www.fwicki.com --- 35 days ago
ROCKVILLE, Md., Sept 8 (Reuters) - The benefits of a proposed Pfizer Inc (PFE.N: Quote , Profile , Research , Stock Buzz ) drug outweigh the risks for some women with osteoporosis, a U.S. advisory Panel decided on Monday. The Panel voted 9-3, with ... ... Source: www.pinoymug.com --- 36 days ago
UPDATE 1-US FDA Panel backs Pfizer osteoporosis drugReuters - 35 minutes agoROCKVILLE, Md., Sept 8 (Reuters) - The benefits of a proposed Pfizer Inc (PFE.N: Quote, Profile, Research, Stock Buzz) osteoporosis drug outweigh the risks for women past menopause with the bone-thinning disease, a US advisory Panel ruled on Monday.Pfizer Bone Drug Benefits Outweigh Risks, Panel Says (Update1) BloombergPfizer to Pitch Treatment For Osteoporosis to FDA 7 Vote(s) ... Source: www.sweetremedy.tv --- 35 days ago
Medical Industry: ... Source: www.themedguru.com --- 28 days ago
... Source: www.fda-news.com --- 33 days ago
FDA Panel Says Pfizer's New Osteoporosis Drug Has Benefits But Use Should Be Restricted (Medical News Today) A Panel that advises the US Food and Drug Administration (FDA) on new drug approvals said the benefits of Pfizer's bone drug Fablyn for treating postmenopausal women with osteoporosis outweighed the risks but that use should be restricted to patients at high risk of fracture or who have tried other treatments without success. MiCardia Corporation Receives US FDA Market Clearance For Dynaplasty Annuloplasty Devices (Medical News Today) MiCardia Corporation announced that the U.S. Food and Drug Administration ("FDA") has granted 510(k) marketing clearance for its Dynaplasty Annuloplasty Band DR and Annuloplasty Ring DR. These are the first of MiCardia's innovative Dynaplasty Technology products to receive clearance. Cardica Receives 510(k) Clearance To Market PAS-Port(R) Proximal Anastomosis System For Use In Cardiac Bypass Surgery (Medical News Today) Cardica, Inc. (Nasdaq: CRDC) announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market its PAS-Port(R) Proximal Anastomosis System for use in cardiac bypass surgery. ... Source: news.google.com --- 36 days ago
Pfizer Bone Drug Benefits Outweigh Risks, Panel Says (Update2) Bloomberg - 33 minutes ago By Justin Blum Sept. 8 (Bloomberg) -- Pfizer Inc.'s Fablyn, an experimental treatment for women with weak bones, has benefits that outweigh its risks, US advisers said. FDA Panel: Pfizer Osteoporosis Drug's Benefits Outweigh Risks CNNMoney.com UPDATE 1-US FDA Panel backs Pfizer osteoporosis drug Reuters Forbes - eFluxMedia - Wall Street Journal all 34 news articles ... Source: blogs.wsj.com --- 12 days ago
A Panel of FDA advisers suggested banning cough and cold medicines for kids under 6. But an agency official suggested yesterday that no such move is imminent. ... Find more results for FDA Panel on RSSMicro.com |
|
Copyright © 2008 RSSMicro.com
